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A single-point mutation in exon 15 of the BRAF gene
has recently been reported in a high percentage in cul-
tured melanoma cells and in 6 of 9 primary melanomas
examined. To evaluate the impact of the T1796A BRAF
mutation, we screened primary melanomas, various types
of nevi and lesions where a melanoma developed in an
underlying nevus.We could detect the mutation in 28 of
97 (29%) melanomas and in 39 of 187 (21%) nevi, includ-
ing blue nevi (0/20) and Spitz nevi (0/69), which did not
carry the mutation. In melanomas with an underlying
nevus, either the mutation was present in both the laser-
microdissected nevus cells and the laser-microdissected
melanoma cells (3/14) or both lesions were negative for
the BRAF mutation except one case. In conclusion, muta-
tions in exon 15 of the BRAF gene are nonspeci¢c for pro-
gression of a nevus to a melanoma. Other so far unknown
cofactors seem to be of importance. Key words: b-raf/
nevus/point mutation. J Invest Dermatol 121:1160 ^1162, 2003
G
enes of the RAF family encode kinases and mediate
cellular responses to growth signals. A recent study
reported about two mutations in exon 15 of the
BRAF gene in a high frequency in melanoma cell
lines, in melanoma short-term cultures, and in 6 of
9 primary melanomas (Davies et al, 2002).TheT1796A single-base
substitution, which was by far the most common mutation
(92%), in one of the coding regions of the BRAF gene leads to
a substitution of valine by glutamic acid at position 599 (V599E).
This probably results in a permanent activation of the mitogen-
activated protein kinase pathway by phosphorylation of T598 and
S601. The prolonged activation of the mitogen-activated protein
kinase pathway has been shown to promote proliferation (Favata
et al, 1998). In melanoma, mitogen-activated protein kinase activa-
tion was reported to be an early event (Cohen et al, 2002), and in
nude mice, a constitutive activation of the pathway leads to a ma-
lignant transformation of melanocytes (Govindarajan et al, 2003).
As CDKN2A, a gene that codes for two proteins p16 and
p14ARF, that are involved in cell cycle regulation (Hashemi et al,
2002), with a frequency of 25% has been the most commonly
mutated gene in melanoma so far, the high frequency of BRAF
mutations was considered to be a possible target of therapy of ad-
vanced stages of melanoma (Pollock and Meltzer, 2002). This
hope was supported by the successful therapeutic application of
the kinase inhibitor STI571 in chronic myeloid leukemia (Druker
et al, 2001).
Davies et al (2002) screened only a small number of primary
melanomas (nine samples) for the presence of the T1796A muta-
tion. Further studies could detect the BRAF exon 15 mutation in
82% of nevocytic nevi (Pollock et al, 2003) and in 22% of sec-
ondary melanomas (Lang et al, 2003).
To evaluate the speci¢city of the BRAF mutation, we screened
a large number of primary melanomas and nonmalignant mela-
nocytic skin lesions. The range of our nevi screened included
both papillomatous nevi, which very rarely develop into mela-
noma, and dysplastic nevi with a higher transformation rate,
whereas Spitz nevi are clinically symmetrically appearing moles
in children and adolescents that histologically resemble melanoma.
To determine the time of occurrence of the speci¢c mutation,
we screened possible precursors of the disease such as dysplastic
nevi and early, noninvasive stages of cancer (melanoma in situ)
for the BRAF mutation. Another aim of our study was to evalu-
ate the presence of the mutation in melanoma in association with
an underlying nevus, because residues of a nevus can histologi-
cally be found in 22% of all melanoma (Stolz et al, 1989).
MATERIALS ANDMETHODS
Study cases and design A total of 312 formalin-¢xed and para⁄n-
embedded biopsies were included in the BRAF exon 15 mutation
screening. Samples included 97 melanomas with 8 melanomas in situ, 14
metastases of melanoma, 98 nevi, 69 Spitz nevi, 20 blue nevi, and 14
melanomas with an underlying nevus (Table I). All samples were either
collected from the ¢les of the Laboratory of Dermatopathology,
Friedrichshafen, or from the Histopathology Section of the Department of
Dermatology, Ludwig-Maximilians-University Munich. All melanomas
were evaluated by at least two experienced dermatopathologists. Institu-
tional approval was obtained for all diagnostic purposes.
Laser-beam microdissection and DNA extraction from captured
cells One 10-mm section cut from the para⁄n-embedded tissue was
stained with hematoxylin. The entire melanocytic in¢ltrate was micro-
dissected with a Pix Cell II laser capture microdissection system (Arcturus
Engineering Inc., Mountain View, CA, USA). In cases of a combined
lesion of a nevus and a melanoma, the nevus cells and melanoma cells
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were microdissected separately (Fig 1). The captured cells were immediately
transferred to proteinase K-enriched digestion bu¡er and incubated at 501C
for 5 to 8 h. Before PCR ampli¢cation, proteinase Kwas inactivated at 951C
for 10 min.
DNA extraction from para⁄n-embedded tissue For DNA
extraction from para⁄n-embedded tissue, we used a modi¢ed version of
the method of Shibata et al (1988). In brief, ¢fteen to twenty 10-mm-thick
sections were cut, depara⁄nized with xylene, and washed with 100%
ethanol. The samples were digested for 2 days with digestion bu¡er and
proteinase K at 371C. DNA was extracted either by phenol/chloroform,
followed by a sodium-acetate precipitation at ^201C overnight, or with
the QIAamp DNA mini kit following the instruction of the supplier
(Qiagen, Hilden Germany).
PCR conditions Speci¢c primers covering exon 15 of the BRAF region
and approximately 50 bases £anking the exon were used (Davies et al,
2002), amplifying a 223-bp product. PCR procedures were carried out at
an annealing temperature of 551C with a MgCl2 concentration of 3.0 mM.
The PCR product (5 mL) was visualized on a 1.5% agarose gel.
Single-strand conformational polymorphism analysis Single-
strand conformational polymorphism analysis was performed using a 10%
polyacrylamide gel with 5% glycerol. The running bu¡er was 1TBE,
and the single-strand conformational polymorphism gels were silver-
stained according to standard procedure. In each single-strand confor-
mational polymorphism reaction a sequence veri¢ed T1796A-positive case
was used as positive control.
Sequencing Samples showing the same single-strand conformational
polymorphism pattern as the sequence veri¢ed T1796A case were
sequenced. Direct sequencing of the PCR products was either performed
with the ABI Prism dye terminator cycle sequencing ready reaction kit
(Applied Biosystems) according to the manufacturer’s guidelines using an
ABI 373 A DNA sequencer (Applied Biosystems) or the PCR products
were puri¢ed with dynabeads (Dynal, Hamburg, Germany) binding to
the biotin-labeled reverse primer, and sequencing was performed on an
automated sequencer (Amersham Biosciences, Sweden) using the ALF
Express AutoRead sequencing kit (Amersham Biosciences). All sequence
changes were veri¢ed by sequencing of both strands.
RESULTS AND DISCUSSION
In our study, we investigated a series of melanocytic skin lesions
for the presence of a speci¢c mutation in exon 15, which has pre-
viously been described (Davies et al, 2002). The speci¢c T1796A
mutation could be seen in 73 of the 312 biopsies screened (23%).
Both the mutation and the wild type could be detected in
Table I. Frequency of T1796A mutations in exon 15 of the
BRAF gene
Mutational frequency
Histologic diagnosis
Sa Laser-beam
microdissectionb
Para⁄n-blockc
Melanoma 28/97 11/38 17/59
Melanoma in situ 0/8 0/6 0/2
Melanoma on nevus
Melanoma 4/14 4/14
Nevus 3/14 3/14
Melanoma metastasis 3/14 3/10 0/4
Blue nevus 0/20 0/20
Spitz nevus 0/69 0/6 0/63
Nevus 39/98 8/30 31/68
Papillomatous nevus
(Unna/Miescher)
20/27 4/10 16/17
Dysplastic nevus 5/28 1/6 4/22
Congenital nevus 6/13 6/13
Dermal nevus 5/23 3/14 2/9
Nevus not further classi¢ed 3/7 3/7
aTotal cases with T1796A BRAF mutation/number of cases screened.
bLaser microdissected cases with T1796A/number of cases screened.
cCases where DNAwas extracted from para⁄n-block with T1796A/number of
cases screened.
Figure1. Laser-beam microdissection
of a melanoma with an underlying
nevus. (A) Nevus part of the lesion before
microdissection; (B) laser-captured nevus
cells (microdissected cells adhering to the
cap); (C) melanoma part of the lesion be-
fore microdissection; (D) laser-captured
melanoma cells (microdissected cells adher-
ing to the cap).
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primary melanoma, dysplastic nevi, papillomatous nevi (Unna/
Miescher) and congenital nevi, whereas only wild-type alleles
were present in all of the blue nevi, Spitz nevi, and melanoma
in situ. The frequency of the speci¢cT1796A mutation in melano-
mas was considerably low (29%) compared to 66% (6 from 9)
in a previous study by Davies et al (2002). None of the melanoma
in situ showed the mutated allele. A similar mutational rate (21%)
was shown in melanoma metastasis. Moreover, we could detect
the mutation in several benign melanocytic lesions with some
types of nevi showing a higher mutational frequency than the
melanoma group. The frequency of the mutation in nevi ranged
from 74% in papillomatous nevi (20 of 27) to 0% in Spitz nevi
(0 of 69) and blue nevi (0 of 20) (Table I).
Besides the small number of cases in the previous study, an-
other reason for the low frequency of BRAF mutations might
be due to contamination by normal cells. Nevertheless, we could
not detect a higher mutation rate for the microdissected samples
compared to those where DNAwas analyzed from the entire sec-
tion. Our data are in harmony with ¢ndings from Lang et al
(2003), who very recently detected T1796A BRAF mutations in
6 of 22 (27%) secondary melanomas.
We also found theT1796A BRAF mutation in various types of
benign nevi. The highest frequency was detected in papilloma-
tous compound nevi, a subgroup of nevi that very rarely pro-
gresses into melanoma. These nevi show within the course of
time physiologic aging with mitotic activity and an increase
in basal melanocytes. This proliferation of melanocytes without
becoming resistant to apoptosis and without acquisition of altered
di¡erentiated functions is a form of senescence (Campisi, 2000)
di¡erent from melanoma cells that progress and ¢nally become
immortal. A mutation in the BRAF gene might therefore not
necessarily mean that those lesions will progress into a melano-
ma, because an oncogenic mutation does not have to cause cancer
(Hanahan and Weinberg, 2000). The fact that BRAF mutations
could not be detected in any Spitz or blue nevi remains unex-
plainable so far. One explanation for the lack of the mutation in
Spitz and blue nevi might be a di¡erent activation of the MAP-
kinase, such as by the ras-oncogene, which is frequently mutated
in Spitz nevi (Bastian et al, 2000). This hypothesis can be sup-
ported by the fact that the melanomas and colon cancers screened
in a previous study (Davies et al, 2002) were solely mutated in
either the b-raf or the h-ras oncogene; an activating mutation of
both genes could not be detected. The most interesting group we
examined were the combined lesions of a melanoma with an
underlying nevus. The melanoma cells and the nevus cells were
microdissected separately, and each part of the lesion screened
for the presence of the BRAF mutation (Fig 1).
Interestingly, we could either detect a mutation in both the ne-
vus and the melanoma (3 the 14) cells or both lesions were wild
type, whereas only one case showed the mutation solely in the
melanoma cells of the lesion. These results con¢rm the theory
that these melanomas did not develop de novo (Urso et al, 1991)
and hint toward the interpretation of the nevus being a precursor
of a melanoma. Our case where the nevus cells were solitarily
wild type might be one of the rare cases where a melanoma did
not show any relationship to the underlying nevus. The melano-
ma cells must have acquired the mutation in the process of
oncogenesis.
Recently, Pollock et al (2003) were the ¢rst to observe T1796A
BRAF mutations in melanocytic nevi with a mutational fre-
quency of 82% (63 of 77 cases). In this study Pollock et al dis-
tinguished between congenital, intradermal, compound, and
dysplastic nevi, which all showed a similar mutational rate. In
our study, we further subgrouped the nevocytic nevi according
to standard histologic practice and could ¢nd large di¡erences in
the various T1796A frequencies depending on the type of nevus
studied. Our mutational frequency ranges from 74% to 0%, with
an average rate of 21%. In addition, Pollock et al did not screen
Spitz nevi, a type of nevus that mimics both clinically and histo-
logically melanoma, nor blue nevi.
In conclusion, by analyzing 312 melanocytic lesions, we de-
tected mutations both in malignant and in nonmalignant mela-
nocytic skin lesions. Owing to these ¢ndings, we can conclude
that theT1796A BRAF mutation alone is not su⁄cient for tumor
development. Further studies are needed to elucidate the impact
of the T1796A mutation on the RAS/RAF/mitogen-activated
protein kinase pathway.
Although we could only detect a mutational frequency of 29%
in all primary melanomas, it is still the single mutation with the
highest frequency in melanomas and hopes remain for BRAF as
a target for a speci¢c kinase inhibitor therapy. The complete lack
of detection in a large population of Spitz nevi (69 cases screened)
might be of diagnostic help, because in unclear histologic cases a
detection of T1796A can be a hint toward the diagnosis of mela-
noma instead of a Spitz nevus.
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